What is the primary purpose of this 10-Q filing?

This 10-Q filing is a quarterly report that Eli Lilly and Company submitted to the U.S. Securities and Exchange Commission (SEC) to provide investors and the public with an update on its financial performance and business operations for the fiscal quarter ending March 30, 1995. It's a mandatory disclosure for publicly traded companies.

Where can I find the detailed financial results for Eli Lilly from this filing?

The provided text is a directory listing from the SEC's EDGAR database and does not contain the detailed financial statements or management discussion. To access the full financial results, you would need to locate and review the actual 10-Q report document, typically available through the SEC's EDGAR database or Eli Lilly's investor relations website.

What kind of information is typically found in a 10-Q filing that would be relevant to investors?

Investors typically look for key financial statements (like the balance sheet, income statement, and cash flow statement), management's discussion and analysis of financial condition and results of operations, any material changes in business, risk factors, legal proceedings, and information about outstanding securities and debt in a 10-Q filing. These elements help assess the company's performance, risks, and future outlook.

Does this filing indicate any specific financial performance metrics or company news?

The provided text is primarily a system directory listing and does not contain specific financial performance metrics, revenue figures, profit margins, or details about the company's products or strategic initiatives. It merely confirms the filing's existence and metadata. To find such information, the full 10-Q document is required.

LLY 10-Q Quarterly Report Q1 FY1995 — Revenue, Net Income, EPS

Summary

Eli Lilly and Company's (LLY) 10-Q filing for the period ending March 30, 1995, provides a snapshot of the company's financial standing early in the year. While detailed financial figures are not directly presented in the provided text, the filing indicates the company is operating and reporting its performance as required by the SEC. Investors would typically look to this report for key performance indicators, revenue trends, profitability, and updates on product pipelines and regulatory matters. This filing, being a quarterly report, would offer investors insights into the company's operational trajectory between full-year reports. It's crucial for understanding the immediate financial health and operational momentum of Eli Lilly, particularly in the context of the pharmaceutical industry's dynamic nature, which is influenced by research and development, patent expirations, and market competition.

Key Highlights

1The filing represents Eli Lilly and Company's (LLY) official 10-Q quarterly report for the period ending March 30, 1995.
2The report was filed with the SEC on May 11, 1995.
3This filing is a routine disclosure for publicly traded companies to provide investors with timely financial information.
4The provided text is a directory listing from the SEC EDGAR system, not the full financial statements.
5Investors would typically review the full 10-Q document for detailed financial statements, management's discussion and analysis, and risk factors.
6The content indicates Eli Lilly is subject to SEC reporting requirements, assuring a level of transparency for investors.

ELI LILLY & Co Quarterly Report for Q1 Ended Mar 31, 1995

Summary

Key Highlights

Frequently Asked Questions